Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Anesthesiology Guidelines
    • Use of uterotonic...

    Use of uterotonic agents during caesarean section: International consensus statement

    Written by Hina Zahid Published On 2019-09-08T19:00:04+05:30  |  Updated On 9 Aug 2021 4:31 PM IST

    An international consensus statement on the use of uterotonic agents during caesarean section has been developed and released.


    It is routine to give a uterotonic drug following delivery of the neonate during caesarean section. However, there is much heterogeneity in the relevant research, which has largely been performed in low‐risk elective cases or women with uncomplicated labour. International guidelines on uterotonic use during caesarean section are variable. Most guidelines make a single recommendation for uterotonic use and do not discuss the use of additional agents in the presence of persistent uterine atony. Management of uterine tone after delivery involves giving a prophylactic uterotonic, and the use of controlled cord traction to facilitate the delivery of the placenta and minimize blood loss. This is usually accomplished with a single drug – however, supplementary drugs are sometimes required.




    Recommendations for clinical practice





    1. Oxytocin or carbetocin are recommended for routine administration immediately after delivery of the fetus during caesarean section to prevent postpartum hemorrhage.

    2. Oxytocin and carbetocin dose requirements for intrapartum caesarean section are several times greater than that for low‐risk elective caesarean section, and therefore a universal dose for all cases is not appropriate.

    3. Oxytocin has significant adverse effects when given as a rapid high‐dose bolus. It should, therefore, be given slowly to reduce these effects. A small initial dose followed by a controlled infusion is the optimum approach. Suggested doses are given in Box.

    4. Research is lacking on oxytocin dose requirements for women having elective caesarean section who are at high risk of uterine atony and hemorrhage. In this situation, it may be appropriate to follow the dose regimen for intrapartum caesarean section.

    5. Infusion regimens for oxytocin are highly variable, but large total oxytocin doses should be avoided to minimize the antidiuretic effect. Administration of a concentrated solution using a syringe pump may be required for women who require fluid restriction.

    6. Carbetocin is a longer‐acting analog of oxytocin, with a similar mechanism of action and adverse effects profile. The increased duration of action of carbetocin compared with oxytocin eliminates the requirement for an infusion after the initial dose. It may, therefore, become the preferred first‐line drug, rather than oxytocin.

    7. If oxytocin/carbetocin do not provide adequate uterine tone, a second‐line drug (ergot alkaloids or a prostaglandin) should be considered early. Administration of a second‐line agent should be guided by the clinical context and presence of contraindications, and follow local hospital policies and availability.

    8. In resource‐constrained settings, where controlled intravenous (i.v.) infusions are not readily available, the intramuscular (i.m.) route can be considered for a sustained duration of drug action.

    9. Women with significant cardiac disease may be very sensitive to the adverse effects of oxytocin and other uterotonics, and their management needs to be individualized.

    10. As accidental administration of uterotonic drugs before delivery of the fetus may result in a catastrophic outcome, extreme care must be taken to ensure that pre‐prepared syringes or solutions are not confused with other drugs that may be given during this period.


    For more details click on the link: https://doi.org/10.1111/anae.14757




    caesareancaesarean sectionCarbetocincardiovascular systemdepressionhypotensionmaternal deathOxytocinplacentaPostpartum haemorrhageprostaglandinstachycardia

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Hina Zahid
    Hina Zahid
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok